Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13830MR)

This product GTTS-WQ13830MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13830MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5296MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ15960MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ6918MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ2497MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ2416MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ1821MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ15316MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ2606MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW